What is Tethis SpA?
Tethis SpA specializes in innovative liquid biopsy solutions, focusing on immediate, automated, and standardized sample processing to ensure integrity. The company's technology is poised to revolutionize cancer management by enabling earlier detection and providing enhanced guidance for treatment strategies. Tethis actively collaborates with various institutions to advance AI-powered liquid biopsy applications and the development of targeted therapies, aiming to make these critical diagnostic tools widely accessible in clinical practice.
How much funding has Tethis SpA raised?
Tethis SpA has raised a total of $16.5M across 1 funding round:
Unspecified
$16.5M
Unspecified (2025): $16.5M with participation from ENEA Tech e Biomedical
Key Investors in Tethis SpA
ENEA Tech e Biomedical
ENEA Tech e Biomedical is a foundation dedicated to investing in technology transfer and biomedical research, aiming to foster innovation and connect research laboratories with biotech companies. They support high-potential startups and SMEs, facilitating academic-industry collaboration to enhance Italy's capabilities in R&D.
What's next for Tethis SpA?
The recent major strategic investment signals a pivotal growth phase for Tethis SpA, likely enabling the company to scale its operations, further refine its AI-driven liquid biopsy technologies, and expand its market reach. This backing is expected to accelerate the integration of their solutions into clinical workflows, supporting the broader adoption of early cancer detection and personalized treatment approaches. The company's focus on collaboration suggests continued efforts to build strategic partnerships for research and development, solidifying its position in the competitive biomedical landscape.
See full Tethis SpA company page
